Skip to content
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Home
Stock Info
NYSE:IGC
Börse Berlín IGS1.BE
Börse frankfurt IGS1.F
Börse Munich IGS1.MU
Börse Stuttgart IGS1.SG
Press Releases
SEC Filing
Company
Our Team
Governance
ESG
Search
Press Releases
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
IGC Pharma Announces a $3 Million Private Placement of its Common Stock – Jul 6’23
July 6, 2023
Read More →
IGC Pharma Receives Notice of Allowance for Patent on Seizures – Jun 6’23
June 6, 2023
Read More →
IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
June 5, 2023
Read More →
IGC Pharma to Present at LD Micro Invitational XIII
May 18, 2023
Read More →
IGC PHARMA to Present at the Planet MicroCap Showcase VEGAS 2023
April 18, 2023
Read More →
Investor Summit March 2023
March 24, 2023
Read More →
IGC Announces Rebranding Changes Name to IGC Pharma Inc
March 20, 2023
Read More →
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
February 14, 2023
Read More →
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
February 8, 2023
Read More →
IGC Receives No objection letter from Health Canada JAN 4. 3023
January 4, 2023
Read More →
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
December 7, 2022
Read More →
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease
December 1, 2022
Read More →
IGC to Present at the RHK 2022 Disruptive Growth Conference
November 30, 2022
Read More →
IGC Reports Financial Results for the Quarter Ended September 30, 2022
November 1, 2022
Read More →
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
September 21, 2022
Read More →
IGC Announces Results of its 2022 Annual Stockholders Meeting
September 12, 2022
Read More →